tapentadol medical valley 200 mg
medical valley invest ab - tapentadoltartrat - depottablett - 200 mg
venlazid 150 mg
medical valley invest ab - venlafaksinhydroklorid - depottablett - 150 mg
venlazid 75 mg
medical valley invest ab - venlafaksinhydroklorid - depottablett - 75 mg
venlazid 225 mg
medical valley invest ab - venlafaksinhydroklorid - depottablett - 225 mg
kaletra
abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infeksjoner - antivirals for systemic use, protease inhibitors - kaletra er angitt i kombinasjon med andre antiretrovirale legemidler til behandling av hiv-1-infiserte voksne, ungdommer og barn i alderen 14 og eldre. valg av kaletra til å behandle protease inhibitor opplevd hiv-1 infiserte pasienter bør være basert på individuelle viral motstand testing og behandling historie av pasienter.
felimazole vet 2.5 mg
dechra limited - tiamazol - tablett, drasjert - 2.5 mg
felimazole vet 1.25 mg
dechra limited - tiamazol - tablett, drasjert - 1.25 mg
felimazole vet 5 mg
dechra limited - tiamazol - tablett, drasjert - 5 mg
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
vidalta vet 15 mg
intervet international bv - 5831 an - karbimazol - depottablett - 15 mg